Consensus Bio-Rad Laboratories, Inc. NYSE

Stocks

BIO.B

US0905721082

Medical Equipment, Supplies & Distribution

Delayed NYSE 21:10:00 20/08/2026 BST			5-day change	1st Jan Change
365.08 ^USD	+8.33%		-.--%	+17.50%

09-09	Bio-Rad Laboratories, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03:45 PM
08-07	RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating	MT

358bdf9eb6456db20b64c8d6.t8OTYTGUvXeTBD7f89qHYWxi0a_8T5LiIvEgGAyuCCE.05n6E13L-Af_RXmPmbL0OCMEiMKPIdqkU6AZIFv-Rhj8-tsxXs7fG8dDcw~e1362f97c77e75a4348144c74c77042d

Analysts' recommendations: Bio-Rad Laboratories, Inc.

08-07	RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating	MT
08-05	RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating	MT
05-15	Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says	MT
04-07	Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375	MT
02-13	UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating	MT
30/10/25	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
03/09/25	RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating	MT
01/08/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating	MT
01/08/25	RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating	MT
01/07/25	RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating	MT
02/05/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating	MT
02/05/25	RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating	MT
08/04/25	RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating	MT
14/02/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating	MT
14/02/25	RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating	MT
04/02/25	RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating	MT
09/12/24	RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating	MT
31/10/24	UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating	MT
01/10/24	Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350	MT
13/09/24	RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating	MT
28/08/24	Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target	MT
02/08/24	Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300	MT
02/08/24	UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating	MT
02/08/24	RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating	MT
24/06/24	RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+17.49%
	MEDTRONIC PLC					+13.21%
	CENCORA, INC.					+15.95%
	BECTON, DICKINSON AND COMPANY					+7.6%
	HOYA CORPORATION					+34.58%
	DEXCOM, INC.					+7.76%
	MEDLINE INC.					+35.19%
	WEST PHARMACEUTICAL SERVICES, INC.					+11.98%
	SARTORIUS STEDIM BIOTECH					+21.45%
	Average					+18.36%
	Weighted average by Cap.					+17.26%